Video

Expert: NIH Encourages Data from Clinical Trials be Disaggregated by Sex in Reporting

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health, discusses how clinical trials have evolved to address biological and sociological variables in patient health.

Pharmacy Times interviewed Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health. Temkin was recently a keynote speaker at the Sex and Gender Health Education Summit, which looked to address the current progress to transform medical education and health care training.

During this discussion, Temkin addresses how clinical trials have evolved to address biological and sociological variables in patient health.

Related Videos
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix